Prospects for a dengue virus vaccine

Stephen S. Whitehead, Joseph E. Blaney, Anna P Durbin, Brian R. Murphy

Research output: Contribution to journalArticle

Abstract

The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.

Original languageEnglish (US)
Pages (from-to)518-528
Number of pages11
JournalNature Reviews Microbiology
Volume5
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Dengue Vaccines
Dengue Virus
Vaccines
Severe Dengue
Central America
Health Priorities
Southeastern Asia
South America
Public Health
Costs and Cost Analysis

ASJC Scopus subject areas

  • Microbiology

Cite this

Whitehead, S. S., Blaney, J. E., Durbin, A. P., & Murphy, B. R. (2007). Prospects for a dengue virus vaccine. Nature Reviews Microbiology, 5(7), 518-528. https://doi.org/10.1038/nrmicro1690

Prospects for a dengue virus vaccine. / Whitehead, Stephen S.; Blaney, Joseph E.; Durbin, Anna P; Murphy, Brian R.

In: Nature Reviews Microbiology, Vol. 5, No. 7, 07.2007, p. 518-528.

Research output: Contribution to journalArticle

Whitehead, SS, Blaney, JE, Durbin, AP & Murphy, BR 2007, 'Prospects for a dengue virus vaccine', Nature Reviews Microbiology, vol. 5, no. 7, pp. 518-528. https://doi.org/10.1038/nrmicro1690
Whitehead, Stephen S. ; Blaney, Joseph E. ; Durbin, Anna P ; Murphy, Brian R. / Prospects for a dengue virus vaccine. In: Nature Reviews Microbiology. 2007 ; Vol. 5, No. 7. pp. 518-528.
@article{6489ccbb86cc41a5b479be095c42c672,
title = "Prospects for a dengue virus vaccine",
abstract = "The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.",
author = "Whitehead, {Stephen S.} and Blaney, {Joseph E.} and Durbin, {Anna P} and Murphy, {Brian R.}",
year = "2007",
month = "7",
doi = "10.1038/nrmicro1690",
language = "English (US)",
volume = "5",
pages = "518--528",
journal = "Nature Reviews Microbiology",
issn = "1740-1526",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Prospects for a dengue virus vaccine

AU - Whitehead, Stephen S.

AU - Blaney, Joseph E.

AU - Durbin, Anna P

AU - Murphy, Brian R.

PY - 2007/7

Y1 - 2007/7

N2 - The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.

AB - The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.

UR - http://www.scopus.com/inward/record.url?scp=34250365710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250365710&partnerID=8YFLogxK

U2 - 10.1038/nrmicro1690

DO - 10.1038/nrmicro1690

M3 - Article

C2 - 17558424

AN - SCOPUS:34250365710

VL - 5

SP - 518

EP - 528

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

SN - 1740-1526

IS - 7

ER -